These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24797802)

  • 1. Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome.
    Mirault T; Rea D; Azarine A; Messas E
    Eur J Haematol; 2015 Apr; 94(4):363-7. PubMed ID: 24797802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Peripheral artery occlusive disease of the lower limbs: Rapid aggravation in a patient taking nilotinib for chronic myeloid leukemia].
    Gautier V; Mirault T; Azarine A; Alsac JM; Sapoval M; Réa D; Messas E
    J Mal Vasc; 2015 Jul; 40(4):231-9. PubMed ID: 26139550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic myeloid leukemia with a novel e8a1 BCR-ABL1 fusion: rapid molecular response with nilotinib.
    Crampe M; Shakkak F; Kelly J; Hodgson A; Langabeer SE
    Leuk Lymphoma; 2017 Sep; 58(9):1-6. PubMed ID: 28121203
    [No Abstract]   [Full Text] [Related]  

  • 4. Optimal Response in a Patient With CML Expressing
    Manzella L; Tirrò E; Vitale SR; Puma A; Consoli ML; Tambè L; Pennisi MS; DI Gregorio S; Romano C; Tomarchio C; DI Raimondo F; Stagno F
    In Vivo; 2020; 34(3):1481-1486. PubMed ID: 32354950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Haguet H; Douxfils J; Mullier F; Chatelain C; Graux C; Dogné JM
    Expert Opin Drug Saf; 2017 Jan; 16(1):5-12. PubMed ID: 27852118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.
    Hochhaus A; Ernst T; Eigendorff E; La Rosée P
    Ann Hematol; 2015 Apr; 94 Suppl 2():S133-40. PubMed ID: 25814079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib.
    Kim TD; Rea D; Schwarz M; Grille P; Nicolini FE; Rosti G; Levato L; Giles FJ; Dombret H; Mirault T; Labussière H; Lindhorst R; Haverkamp W; Buschmann I; Dörken B; le Coutre PD
    Leukemia; 2013 Jun; 27(6):1316-21. PubMed ID: 23459449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nilotinib-Associated Atherosclerosis Presenting as Multifocal Intracranial Stenosis and Acute Stroke.
    Kakadia B; Thakkar R; Sanborn E; Suero-Abreu GA; Jovin TG; Then R
    J Stroke Cerebrovasc Dis; 2021 Aug; 30(8):105883. PubMed ID: 34090174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
    Hughes T; Saglio G; Branford S; Soverini S; Kim DW; Müller MC; Martinelli G; Cortes J; Beppu L; Gottardi E; Kim D; Erben P; Shou Y; Haque A; Gallagher N; Radich J; Hochhaus A
    J Clin Oncol; 2009 Sep; 27(25):4204-10. PubMed ID: 19652056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of psoriasis in a patient with chronic myelogenous leukaemia during nilotinib treatment.
    Nagai T; Karakawa M; Komine M; Muroi K; Ohtsuki M; Ozawa K
    Eur J Haematol; 2013 Sep; 91(3):270-272. PubMed ID: 23734955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment.
    Gora-Tybor J; Medras E; Calbecka M; Kolkowska-Leśniak A; Ponikowska-Szyba E; Robak T; Jamroziak K
    Leuk Lymphoma; 2015; 56(8):2309-14. PubMed ID: 25563556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.
    Massimino M; Stella S; Tirrò E; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Tomarchio C; DI Raimondo F; Manzella L
    Anticancer Res; 2020 May; 40(5):2457-2465. PubMed ID: 32366389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Irvine E; Williams C
    Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nilotinib-Associated Multiple Silent Arterial Stenoses in a Patient with Chronic Myeloid Leukemia.
    Tokatlı M; Ismayilov R; Erkin Çınar O; Haznedaroğlu İC
    Turk J Haematol; 2024 Mar; 41(1):59-60. PubMed ID: 38153228
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical cardiac safety profile of nilotinib.
    Kim TD; le Coutre P; Schwarz M; Grille P; Levitin M; Fateh-Moghadam S; Giles FJ; Dörken B; Haverkamp W; Köhncke C
    Haematologica; 2012 Jun; 97(6):883-9. PubMed ID: 22271904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nilotinib-induced liver injury: A case report.
    Tan Y; Ye Y; Zhou X
    Medicine (Baltimore); 2020 Sep; 99(36):e22061. PubMed ID: 32899072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
    Okabe S; Tauchi T; Tanaka Y; Kitahara T; Kimura S; Maekawa T; Ohyashiki K
    Cancer Biol Ther; 2014 Feb; 15(2):207-15. PubMed ID: 24100660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.
    Aichberger KJ; Herndlhofer S; Schernthaner GH; Schillinger M; Mitterbauer-Hohendanner G; Sillaber C; Valent P
    Am J Hematol; 2011 Jul; 86(7):533-9. PubMed ID: 21538470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.